This is the Continuous Integration Build of FHIR (will be incorrect/inconsistent at times).
See the Directory of published versions
Biomedical Research and Regulation Work Group | Maturity Level: N/A | Standards Status: Informative | Compartments: No defined compartments |
Raw JSON (canonical form + also see JSON Format Specification)
Indication example
{ "resourceType" : "ClinicalUseDefinition", "id" : "example-indication", "text" : { "status" : "extensions", "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Generated Narrative: ClinicalUseDefinition</b><a name=\"example-indication\"> </a><a name=\"hcexample-indication\"> </a></p><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Resource ClinicalUseDefinition "example-indication" </p></div><p><b>StructureDefinition Work Group</b>: brr</p><p><b>type</b>: indication</p><p><b>subject</b>: <a href=\"medicinalproductdefinition-example.html\">MedicinalProductDefinition/example</a></p><blockquote><p><b>indication</b></p><h3>DiseaseSymptomProcedures</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td>Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (indicationasdisease-symptom-procedure#Pulmonary-embolism-and-thrombosis-example-code)</span></td></tr></table><h3>DiseaseStatuses</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td>Recurrent <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (diseasestatus#Recurrent)</span></td></tr></table><h3>IntendedEffects</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td>PRYLX <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (intendedeffect#PRYLX)</span></td></tr></table></blockquote><p><b>population</b>: <a name=\"hcgroup\"> </a></p><blockquote><p/><p><a name=\"group\"> </a></p><p><a name=\"hcgroup\"> </a></p><p><b>type</b>: person</p><p><b>membership</b>: definitional</p><h3>Characteristics</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td><td><b>Exclude</b></td></tr><tr><td style=\"display: none\">*</td><td>age-range <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (characteristic#age-range)</span></td><td>18-? a</td><td>false</td></tr></table></blockquote><hr/><blockquote><p><b>Generated Narrative: Group #group</b><a name=\"group\"> </a><a name=\"hcgroup\"> </a></p><p><b>type</b>: person</p><p><b>membership</b>: definitional</p><h3>Characteristics</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td><td><b>Exclude</b></td></tr><tr><td style=\"display: none\">*</td><td>age-range <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (characteristic#age-range)</span></td><td>18-? a</td><td>false</td></tr></table></blockquote></div>" }, "contained" : [{ "resourceType" : "Group", "id" : "group", "type" : "person", "membership" : "definitional", "characteristic" : [{ "code" : { "coding" : [{ "system" : "http://ema.europa.eu/example/characteristic", "code" : "age-range" }] }, "valueRange" : { "low" : { "value" : 18, "unit" : "a" } }, "exclude" : false }] }], "extension" : [{ "url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-wg", "valueCode" : "brr" }], "type" : "indication", "subject" : [{ "reference" : "MedicinalProductDefinition/example" }], "indication" : { "diseaseSymptomProcedure" : { "concept" : { "coding" : [{ "system" : "http://ema.europa.eu/example/indicationasdisease-symptom-procedure", "code" : "Pulmonary-embolism-and-thrombosis-example-code" }], "text" : "Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults." } }, "diseaseStatus" : { "concept" : { "coding" : [{ "system" : "http://ema.europa.eu/example/diseasestatus", "code" : "Recurrent" }] } }, "intendedEffect" : { "concept" : { "coding" : [{ "system" : "http://ema.europa.eu/example/intendedeffect", "code" : "PRYLX" }] } } }, "population" : [{ "reference" : "#group" }] }
Usage note: every effort has been made to ensure that the examples are correct and useful, but they are not a normative part of the specification.
FHIR ®© HL7.org 2011+. FHIR R6 hl7.fhir.core#6.0.0-cibuild generated on Thu, Apr 25, 2024 12:45+0000.
Links: Search |
Version History |
Contents |
Glossary |
QA |
Compare to R5 |
|
Propose a change